Methodological issues, such as study design, patient selection bias and heterogeneity of biochemical measurements, are potential drawbacks of nearly all studies in acromegaly. Case series ...

Biochemical control of acromegaly in noncured patients is usually defined as serum growth hormone (GH) levels <2.0 µg/l, plus normal-for-age serum levels of insulin-like growth factor I (IGF-I).

The partnership focused on an integrated and accelerated chemistry, manufacturing, and controls (CMC) program for MAR002, Marea's investigational anti-growth hormone receptor (GHR) antibody for the ...